The eligibility criteria for this systematic review were meticulously designed to focus exclusively on randomized controlled trials (RCTs) and clinical trials that compare the efficacy and long-term outcomes of beta-blockers versus ACE inhibitors in the management of chronic heart failure (CHF). The gene discussed is ACE; the disease is congestive heart failure.